Clinicopathological characteristics of the CD19⁺MRD/relapse, CD19^–MRD/relapse, and no-MRD^–-remission categories after CAR T-cell therapy. Age, prior blinatumomab treatment, and CD19 expression levels on blasts, before CAR T-cell infusion are shown. HP-4 and H-53 had false-positive MRD at day 28 assessment and remained in remission without further therapy at data cutoff.